US FDA Maps Out Novel Path For Developers Of Next Gen Sequencing Products
This article was originally published in SRA
Executive Summary
Two guidances issued by the US Food and Drug Administration on next-generation sequencing map out approaches for NGS developers to bring their products to market by relying on established standards and databases rather than new clinical studies to validate individual markers1-3.
You may also be interested in...
Boehringer Ingelheim Overtakes Bayer As Germany’s Biggest Pharma Company
The privately owned company is searching for a successor to Jardiance, while the outcome of US Inflation Reduction Act talks on price cuts to the blockbuster will be revealed in September.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Swisse Supplements Take Bigger Slice Of Chinese Market
Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.